2025 CPEO Summit Highlights: Huluwa Pharmaceutical Group Empowers Pediatric Pharmaceuticals Through "Diversified Innovation"

On August 17, the CPEO Summit (China Health Industry Ecology Conference), widely regarded as the "Davos of the health industry", was grandly opened in Boao, Hainan. Liu Jingping, Party Secretary and Chairperson of Huluwa Pharmaceutical Group, attended the opening ceremony as a guest of honor. She was also presented with an industry award at the "Awakening is Power - Entrepreneurs' Night" event, highlighting the company's benchmark position in China's pediatric pharmaceutical sector.

 As a well-known domestic pediatric pharmaceutical company, Huluwa Pharmaceutical Group has leveraged innovation platforms including the Academician Zhang Qiang Workstation, the Hainan Provincial Engineering Research Center for Traditional Chinese Medicine Preparations, and the Postdoctoral Research Station to build a "full-life-cycle pediatric health product portfolio", serving over ten million children. Since the beginning of this year, the Group has obtained approvals for major new products such as Salbutamol Sulfate Solution for Inhalation and Calcitriol Soft Capsules. The total number of generic drugs that have passed consistency evaluation has increased to 28, and the development of seven Class I innovative traditional Chinese medicines is progressing smoothly, covering high-incidence pediatric diseases in areas such as the respiratory and digestive systems. Among them, novel dosage forms such as inhalation formulations and orally disintegrating films are primarily designed to address medication adherence challenges in children.